阿奇霉素治疗小儿支原体肺炎患儿的临床疗效

目的 研究阿奇霉素治疗小儿支原体肺炎患儿的临床疗效与价值.方法 80例小儿支原体肺炎患儿,采用双盲法分为对照组及实验组,每组40例.对照组接受常规对症治疗,实验组在常规对症治疗基础上联用阿奇霉素治疗.对比两组患儿的治疗效果、炎症指标水平、血气指标、症状缓解时间以及不良反应发生率.结果 实验组治疗后C反应蛋白(CRP)水...

Clinical efficacy of azithromycin in the treatment of children with mycoplasma pneumonia

Objective To study the clinical efficacy and value of azithromycin in the treatment of children with mycoplasma pneumonia. Methods A total of 80 children with mycoplasma pneumonia were divided into control group and experimental group by double-blind method, with 40 cases in each group. The control group received conventional symptomatic treatment, and the experimental group was treated with azithromycin in combination with conventional symptomatic treatment. The therapeutic effect, inflammation index level, blood gas index, symptom relief time and the incidence of adverse reactions were compared between the two groups.Results After treatment, the C-reactive protein(CRP)(3.2±1.5) mg/L of the experimental group was lower than(5.9±2.9) mg/L of the control group, and the difference was statistically significant(P<0.05). After treatment,the partial pressure of carbon dioxide(41.3±4.1) mm Hg(1 mm Hg=0.133 kPa) of the experimental group was lower than(50.7±6.1) mm Hg of the control group, and the partial pressure of oxygen(83.7±7.2) mm Hg was higher than(73.2±10.4) mm Hg of the control group. All the differences were statistically significant(P<0.05). The hospitalization time, cough disappearance time, body temperature return to normal time, and lung rale disappearance time in the experimental group were shorter than those in the control group, and the difference was statistically significant(P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups(P<0.05). The total effective rate 100.0% in the experimental group was higher than 87.5% in the control group, and the difference was statistically significant(P<0.05). Conclusion In the treatment of children with mycoplasma pneumonia, the combination of azithromycin on the basis of conventional symptomatic treatment can significantly improve the inflammation and blood gas index of the children, shorten the recovery time of the children and improve the efficiency of treatment, and at the same time, the drug is safer and less likely to cause serious drug reactions in the children. It contains the value of promotion and application.